Celgene Corp. agreed to buy blood-disease biotechnology company Impact Biomedicines for as much as $7 billion.
Celgene will make an upfront payment of $1.1 billion for the privately held San Diego company, the companies said in a statement Sunday, confirming an earlier report in The Wall Street Journal.
Assuming Impact hits regulatory-approval... 